Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6783939B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 16, 2001 |
| Grant date | Aug 31, 2004 |
| Priority date | — |
| Expiry date | Feb 18, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/36151
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a g&agr;g gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the g&agr;g gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the g&agr;g gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.